Multiple myeloma: the present and the future

Douglas E Joshua
Med J Aust 2005; 183 (7): . || doi: 10.5694/j.1326-5377.2005.tb07079.x
Published online: 3 October 2005

Major advances continue apace in therapy and in understanding its molecular pathogenesis

Myeloma is a malignancy of plasma cells in the bone marrow and presents with bone lesions, renal failure, anaemia and hypercalcaemia. Back pain, often associated with vertebral body collapse, is the most common presenting feature. In Australia, about 1200 new patients are diagnosed with multiple myeloma each year, with a median age at diagnosis in the early 60s.

  • Douglas E Joshua

  • Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW.


Competing interests:

I am an advisory consultant to Pharmion, Janssen-Cilag and Novartis, and received assistance from Novartis to attend the 2004 meeting of the American Society of Haematology.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.